FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034361618> ?p ?o ?g. }

• W2034361618 endingPage "221" @default.
• W2034361618 startingPage "215" @default.
• W2034361618 abstract "Pro-inflammatory cytokine over-expression may be implicated to the pathogenesis of anemia in chronic heart failure (CHF) through the suppression of bone marrow erythropoiesis. Erythropoietin administration has anti-inflammatory and anti-apoptotic properties in experimental CHF models and improves exercise capacity in anemic CHF patients. The present study investigates the effects of recombinant human erythropoietin analogue darbepoetin-alpha on circulating pro-inflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with CHF and anemia. Forty-one CHF patients (NYHA class: II-III; left ventricular (LV) ejection fraction (EF) <40%; hemoglobin <12.5g/dl; serum creatinine <2.5mg/dl) were randomized to receive either 3-month darbepoietin-* at 1.5 microg/kg every 20 days plus iron orally (n=21) or placebo plus iron orally (n=20). LV systolic function, plasma B-type natriuretic peptide (BNP), inflammatory markers (TNF-*, IL-6, CRP), anti-inflammatory cytokine IL-10, endothelial adhesion molecules (soluble ICAM-1 and VCAM-1) and soluble apoptosis mediators (soluble Fas, soluble Fas ligand), and 6-min walking distance were assessed at baseline and 3 months post-treatment. In darbepoetin-* treated patients, plasma BNP (451 (62-2770) from 802 (476-4440) pg/ml, p=0.002), IL-6 (6.5+/-4.7 from 10.5+/-7.8 pg/ml, p=0.013) and soluble Fas ligand (53.2+/-16.6 from 59.2+/-17.9 pg/ml, p=0.023) decreased significantly, while LVEF (32+/-6 from 26+/-6%, p<0.001), hemoglobin (12.8+/-1.4 from 10.9+/-1.0 g/dl, p<0.001) and 6-min walked distance (274+/-97 from 201+/-113m, p<0.01) increased significantly. No significant changes were observed in the placebo arm, except for a worsening in 6-min walked distance (p=0.044). In conclusion, darbepoetin-alpha reduces circulating pro-inflammatory cytokine IL-6 and apoptotic mediator soluble Fas ligand in CHF patients with anemia, with a parallel improvement of cardiac performance and exercise capacity." @default.
• W2034361618 created "2016-06-24" @default.
• W2034361618 creator A5004976864 @default.
• W2034361618 creator A5006839827 @default.
• W2034361618 creator A5013454631 @default.
• W2034361618 creator A5023320363 @default.
• W2034361618 creator A5058149130 @default.
• W2034361618 creator A5062238016 @default.
• W2034361618 creator A5083351017 @default.
• W2034361618 creator A5040478827 @default.
• W2034361618 date "2008-07-01" @default.
• W2034361618 modified "2023-09-23" @default.
• W2034361618 title "Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure" @default.
• W2034361618 cites W162820025 @default.
• W2034361618 cites W1965282498 @default.
• W2034361618 cites W1970720507 @default.
• W2034361618 cites W1972185183 @default.
• W2034361618 cites W1977017159 @default.
• W2034361618 cites W1982047573 @default.
• W2034361618 cites W1988495648 @default.
• W2034361618 cites W2000636214 @default.
• W2034361618 cites W2023078367 @default.
• W2034361618 cites W2024111595 @default.
• W2034361618 cites W2027712499 @default.
• W2034361618 cites W2030718449 @default.
• W2034361618 cites W2054849245 @default.
• W2034361618 cites W2058141781 @default.
• W2034361618 cites W2058454611 @default.
• W2034361618 cites W2065629260 @default.
• W2034361618 cites W2071524275 @default.
• W2034361618 cites W2075427055 @default.
• W2034361618 cites W2077316495 @default.
• W2034361618 cites W2082665949 @default.
• W2034361618 cites W2086057525 @default.
• W2034361618 cites W2099348212 @default.
• W2034361618 cites W2099867389 @default.
• W2034361618 cites W2104179458 @default.
• W2034361618 cites W2105487937 @default.
• W2034361618 cites W2108712459 @default.
• W2034361618 cites W2122817227 @default.
• W2034361618 cites W2123200029 @default.
• W2034361618 cites W2142984634 @default.
• W2034361618 cites W2153903059 @default.
• W2034361618 cites W2166894412 @default.
• W2034361618 cites W2990123797 @default.
• W2034361618 doi "https://doi.org/10.1016/j.atherosclerosis.2007.09.039" @default.
• W2034361618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17991471" @default.
• W2034361618 hasPublicationYear "2008" @default.
• W2034361618 type Work @default.
• W2034361618 sameAs 2034361618 @default.
• W2034361618 citedByCount "43" @default.
• W2034361618 countsByYear W20343616182012 @default.
• W2034361618 countsByYear W20343616182013 @default.
• W2034361618 countsByYear W20343616182014 @default.
• W2034361618 countsByYear W20343616182015 @default.
• W2034361618 countsByYear W20343616182016 @default.
• W2034361618 countsByYear W20343616182018 @default.
• W2034361618 countsByYear W20343616182021 @default.
• W2034361618 countsByYear W20343616182023 @default.
• W2034361618 crossrefType "journal-article" @default.
• W2034361618 hasAuthorship W2034361618A5004976864 @default.
• W2034361618 hasAuthorship W2034361618A5006839827 @default.
• W2034361618 hasAuthorship W2034361618A5013454631 @default.
• W2034361618 hasAuthorship W2034361618A5023320363 @default.
• W2034361618 hasAuthorship W2034361618A5040478827 @default.
• W2034361618 hasAuthorship W2034361618A5058149130 @default.
• W2034361618 hasAuthorship W2034361618A5062238016 @default.
• W2034361618 hasAuthorship W2034361618A5083351017 @default.
• W2034361618 hasConcept C126322002 @default.
• W2034361618 hasConcept C134018914 @default.
• W2034361618 hasConcept C185592680 @default.
• W2034361618 hasConcept C190283241 @default.
• W2034361618 hasConcept C203014093 @default.
• W2034361618 hasConcept C2775915353 @default.
• W2034361618 hasConcept C2776914184 @default.
• W2034361618 hasConcept C2778198053 @default.
• W2034361618 hasConcept C2778248108 @default.
• W2034361618 hasConcept C2778534260 @default.
• W2034361618 hasConcept C2778690821 @default.
• W2034361618 hasConcept C2781404941 @default.
• W2034361618 hasConcept C31573885 @default.
• W2034361618 hasConcept C55493867 @default.
• W2034361618 hasConcept C66008609 @default.
• W2034361618 hasConcept C71924100 @default.
• W2034361618 hasConcept C78085059 @default.
• W2034361618 hasConceptScore W2034361618C126322002 @default.
• W2034361618 hasConceptScore W2034361618C134018914 @default.
• W2034361618 hasConceptScore W2034361618C185592680 @default.
• W2034361618 hasConceptScore W2034361618C190283241 @default.
• W2034361618 hasConceptScore W2034361618C203014093 @default.
• W2034361618 hasConceptScore W2034361618C2775915353 @default.
• W2034361618 hasConceptScore W2034361618C2776914184 @default.
• W2034361618 hasConceptScore W2034361618C2778198053 @default.
• W2034361618 hasConceptScore W2034361618C2778248108 @default.
• W2034361618 hasConceptScore W2034361618C2778534260 @default.
• W2034361618 hasConceptScore W2034361618C2778690821 @default.
• W2034361618 hasConceptScore W2034361618C2781404941 @default.
• W2034361618 hasConceptScore W2034361618C31573885 @default.

• next